MX2009009132A - Composiciones medicinales mejoradas que comprenden buprenorfina y naltrexona. - Google Patents

Composiciones medicinales mejoradas que comprenden buprenorfina y naltrexona.

Info

Publication number
MX2009009132A
MX2009009132A MX2009009132A MX2009009132A MX2009009132A MX 2009009132 A MX2009009132 A MX 2009009132A MX 2009009132 A MX2009009132 A MX 2009009132A MX 2009009132 A MX2009009132 A MX 2009009132A MX 2009009132 A MX2009009132 A MX 2009009132A
Authority
MX
Mexico
Prior art keywords
naltrexone
buprenorphine
medicinal compositions
improved medicinal
dosage form
Prior art date
Application number
MX2009009132A
Other languages
English (en)
Spanish (es)
Inventor
Christopher Bourne Chapleo
Neil Hyde
Original Assignee
Reckitt Benckiser Healthcare
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37965733&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009009132(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Reckitt Benckiser Healthcare filed Critical Reckitt Benckiser Healthcare
Publication of MX2009009132A publication Critical patent/MX2009009132A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2009009132A 2007-03-01 2008-02-15 Composiciones medicinales mejoradas que comprenden buprenorfina y naltrexona. MX2009009132A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0703966A GB2447014A (en) 2007-03-01 2007-03-01 Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
PCT/GB2008/000521 WO2008104735A1 (en) 2007-03-01 2008-02-15 Improved medicinal compositions comprising buprenorphine and naltrexone

Publications (1)

Publication Number Publication Date
MX2009009132A true MX2009009132A (es) 2009-09-03

Family

ID=37965733

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009132A MX2009009132A (es) 2007-03-01 2008-02-15 Composiciones medicinales mejoradas que comprenden buprenorfina y naltrexona.

Country Status (21)

Country Link
US (1) US8912211B2 (enExample)
EP (1) EP2125019B1 (enExample)
JP (1) JP5577101B2 (enExample)
KR (1) KR20090115861A (enExample)
CN (1) CN101622014A (enExample)
AR (1) AR065580A1 (enExample)
AU (1) AU2008220620A1 (enExample)
BR (1) BRPI0807902A2 (enExample)
CA (1) CA2678481C (enExample)
CL (1) CL2008000608A1 (enExample)
DK (1) DK2125019T3 (enExample)
ES (1) ES2475734T3 (enExample)
GB (1) GB2447014A (enExample)
HR (1) HRP20140592T1 (enExample)
MX (1) MX2009009132A (enExample)
PE (1) PE20081799A1 (enExample)
PL (1) PL2125019T3 (enExample)
PT (1) PT2125019E (enExample)
TW (1) TW200836737A (enExample)
WO (1) WO2008104735A1 (enExample)
ZA (1) ZA200905689B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9095548B2 (en) 2010-04-29 2015-08-04 Allodynic Therapeutics, Llc Combinations of opioid/TLR4 antagonists and acetyl-para-aminophenol (APAP) for use in the treatment of pain
US9205081B2 (en) 2010-04-29 2015-12-08 Allodynic Therapeutics, Llc Combinations of opiod/TLR4 antagonist and a cyclooxygenase (COX) inhibitor for use in the treatment of pain
ME02367B (me) * 2010-09-21 2016-06-20 Purdue Pharma Lp Analozi buprenorfina kao agonisti i/ili antagonisti opioidnog receptora
EP2968293A4 (en) * 2013-03-13 2016-12-28 Allodynic Therapeutics Llc PAIN RELIEF COMPOSITIONS COMPRISING AN OPIOID / TOLL LIKE RECEPTOR 4 ANTAGONIST, DEXTROENANTIOMERS, AND METHOD OF USE THEREOF
US20160120861A1 (en) * 2013-06-28 2016-05-05 Purdue Pharma L.P. Compositions and Methods for Treating an Arrhythmia with an Opioid Antagonist
US9918981B2 (en) 2013-09-10 2018-03-20 Insys Development Company, Inc. Liquid buprenorphine formulations
US9867818B2 (en) 2013-09-10 2018-01-16 Insys Development Company, Inc. Sublingual buprenorphine spray
US9839611B2 (en) 2013-09-10 2017-12-12 Insys Development Company, Inc. Sublingual buprenorphine spray
DK3043777T3 (da) 2013-09-10 2020-07-20 Fresh Cut Dev Llc Sublingual buprenorphinspray
US10617686B2 (en) 2014-07-08 2020-04-14 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
EP3177146A4 (en) 2014-07-08 2018-01-03 Insys Pharma, Inc. Sublingual naloxone spray
US10722510B2 (en) 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
WO2018081792A2 (en) 2016-10-31 2018-05-03 Allodynic Therapeutics, Llc Combinations of opioid/tlr4 antagonists and acetaminophen for use in the treatment of emotional pain and insomnia
US12343340B2 (en) 2020-12-31 2025-07-01 Soin Therapeutics Llc Methods of using low dose naltrexone to treat chronic pain
US11752143B2 (en) 2020-12-31 2023-09-12 Soin Therapeutics Llc Methods of using low dose naltrexone to treat chronic pain

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US572149A (en) * 1896-12-01 Tobacco-cutting machine
GB8430346D0 (en) 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
GB8728294D0 (en) * 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US5272149A (en) * 1992-05-05 1993-12-21 Stalling Reginald W Symptom controlled receptor substitution for addiction withdrawl
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
CN1204890C (zh) 1997-12-22 2005-06-08 欧罗赛铁克股份有限公司 防止阿片样物质滥用的方法
AR031682A1 (es) * 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
SI2283842T1 (sl) * 2000-02-08 2015-07-31 Euro-Celtique S.A. Oralne formulacije opioidnih agonistov, varne pred zlorabo
US20050191340A1 (en) * 2002-08-09 2005-09-01 Gruenenthal Gmbh Opioid-receptor antagonists in transdermal systems having buprenorphine

Also Published As

Publication number Publication date
JP2010520183A (ja) 2010-06-10
US20100120812A1 (en) 2010-05-13
ZA200905689B (en) 2010-10-27
KR20090115861A (ko) 2009-11-09
GB0703966D0 (en) 2007-04-11
WO2008104735A1 (en) 2008-09-04
CN101622014A (zh) 2010-01-06
DK2125019T3 (da) 2014-06-30
AR065580A1 (es) 2009-06-17
TW200836737A (en) 2008-09-16
US8912211B2 (en) 2014-12-16
JP5577101B2 (ja) 2014-08-20
BRPI0807902A2 (pt) 2014-06-17
ES2475734T3 (es) 2014-07-11
AU2008220620A1 (en) 2008-09-04
PL2125019T3 (pl) 2014-08-29
HRP20140592T1 (hr) 2014-09-12
EP2125019B1 (en) 2014-04-09
PT2125019E (pt) 2014-07-11
CA2678481A1 (en) 2008-09-04
CA2678481C (en) 2014-11-18
CL2008000608A1 (es) 2008-10-03
EP2125019A1 (en) 2009-12-02
GB2447014A (en) 2008-09-03
PE20081799A1 (es) 2008-12-18

Similar Documents

Publication Publication Date Title
MX2009009131A (es) Mejoras en y con relacion a composiciones medicinales.
JP2010520186A5 (enExample)
MX2009009133A (es) Composiciones medicinales mejoradas que comprenden buprenorfina y naloxona.
MX2009009134A (es) Composiciones medicinales mejoradas que comprenden buprenorfina y nalmefeno.
HRP20140592T1 (hr) Poboljšani medicinski pripravci koji sadrže buprenorfin i naltrekson
JP2010520183A5 (enExample)
NZ605887A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
NZ595467A (en) Sublingual pharmaceutical composition comprising a neutral oil
MX2009002314A (es) Composiciones farmaceuticas que comprenden hgh para suministro oral.
NZ597378A (en) Treatment of multiple sclerosis with laquinimod
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
WO2008085765A3 (en) Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
MX2010005631A (es) Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades.
WO2010033188A3 (en) Dosages for menstrual suppression, contraception, and hormone replacement therapy, and methods of administering same
MY173215A (en) Acetylcysteine compositions and methods of use thereof
WO2012007159A3 (en) Novel gastro-retentive dosage forms
IL196425A0 (en) Pharmaceutical compositions containing ibuprofen and famotidine
WO2007012019A3 (en) Medicaments containing famotidine and ibuprofen and administration of same
NZ595046A (en) Compositions and methods for extended therapy with aminopyridines
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
NZ617397A (en) Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units
JP2010520184A5 (enExample)
WO2012042197A3 (en) Low dose pharmaceutical composition comprising zanamivir
WO2008106689A3 (en) Breakthrough pain management
NZ719087A (en) Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: RB PHARMACEUTICALS LIMITED.*

FG Grant or registration